Compare Novavax Inc (NVAX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Royal Caribbean Cruises Ltd — how do they compare? Novavax Inc trades at $12.79 (market cap $1.82B), while Royal Caribbean Cruises Ltd trades at $281.02 (market cap $75.26B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 41.4× Novavax Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| NVAX | RCL | |
|---|---|---|
Market Cap | $1.82B | $75.26B |
Volume | 6,198,505 | 1,958,628 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $348.03 |
52-Week Low | $6.22 | $230.30 |
Typical Hold Time | 59 Days | 85 Days |
Enterprise Value | $1.39B | $97.91B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Royal Caribbean (RCL) trades at $280.65, down 0.61% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $17.93B, net income of $4.27B (23.54% margin), and consistent earnings beats in recent quarters. Recent news highlights include a $3B investment in Sandals Resorts and positive analyst sentiment with 52.83% buy ratings.
RCL presents a compelling growth story with strong profitability and expansion initiatives, though risks include high debt levels and fuel cost exposure. The consensus price target of $346.67 suggests 23.5% upside potential, supported by improving cash flow trends and strategic diversification into resort operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
